Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Safety of Pasireotide Long Acting Release (LAR) in Combination With Weekly Pegvisomant in Previously Controlled Acromegaly Patients on Combination Treatment of Long-Acting Somatostatin Analogues and Weekly Pegvisomant

Trial Profile

Efficacy and Safety of Pasireotide Long Acting Release (LAR) in Combination With Weekly Pegvisomant in Previously Controlled Acromegaly Patients on Combination Treatment of Long-Acting Somatostatin Analogues and Weekly Pegvisomant

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 26 Dec 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 27 May 2020 Results (n=45) assessing relationship between the predictors and the hormonal and tumoral responses to long-acting pasireotide (PAS-LAR) therapy compared with responsiveness to first-generation somatostatin receptor ligands, published in the European Journal of Endocrinology.
  • 18 Mar 2019 Results assessing T2-signal intensity and SST receptor expression in relation to the hormone and tumor response during PAS-LAR treatment presented at the 101st Annual Meeting of the Endocrine Society
  • 12 Oct 2018 Results (n=59) of the extension study of 48 weeks ,published in the European Journal of Endocrinology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top